Advances and Implications in Nanotechnology for Lung Cancer Management

Author(s): Sana Sarkar, Khwaja Osama, Qazi Mohammad Sajid Jamal, Mohammad Amjad Kamal, Usman Sayeed, M. Kalim A. Khan, Mohd. Haris Siddiqui, Salman Akhtar.

Journal Name: Current Drug Metabolism

Volume 18 , Issue 1 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Lung cancer is one of the most fatal chronic diseases in the field of respiratory medicine. The purpose of this paper is to address the side effects of conventional treatment strategies and to report the findings of till date drug nanocarriers researches performed for lung cancer therapy. This review also highlights the outstanding results of several researches employing pulmonary delivery system of nano-based drug formulations suitable for lung cancer.

Objective: Summarizing the advances made in the field of nanotechnology-based lung cancer management.

Methods: We systematically searched for research literature using a well-framed review question and presented data in the tabular forms for readers’ convenience.

Results: Sixty-four papers were included in the review, the majority of which represent latest researches in the field of nanoparticle-based drug delivery for lung cancer therapy. Conventional treatment strategies for lung cancer lack specificity and are limited by undesirable toxicities in normal cells, as well as a high rate of recurrence. Intervention of nanotechnology has revolutionized the therapy of lung cancer upto a great extent by overcoming the current constraints in conventional therapies. Pulmonary delivery of nano-based drug formulations has resulted in potentially more effective and advanced lung cancer therapy.

Conclusion: Several nanoscale drug delivery systems for lung cancer treatment are at present in clinical trials and some of them already exist in commercially available forms in the marketplace. However, although nanoscale drug carriers for lung cancer treatment have demonstrated stupendous therapeutic potential at both preclinical and clinical trials, but there are still many limitations to be solved.

Keywords: Lung cancer, Muti drug resistance, nano carriers, nanoparticles, passive and active targeting, pulmonary drug delivery.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 18
ISSUE: 1
Year: 2017
Page: [30 - 38]
Pages: 9
DOI: 10.2174/1389200218666161114142646
Price: $58

Article Metrics

PDF: 33
HTML: 1